AMCP 2020


Enfortumab Vedotin | Urothelial Carcinoma | Abstract C32

Real-World Outcomes With Taxane Monotherapy Following Platinum and Anti-Programmed Death 1/Death-Ligand 1 Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract C33

Quality of Life of Metastatic Urothelial Cancer Patients Treated With Enfortumab Vedotin Following Platinum-containing Chemotherapy and a Checkpoint Inhibitor: Data From EV-201 Cohort 1

Research | Breast Cancer | Abstract C20

Epidemiology of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the United States in 2019

Brentuximab Vedotin | Lymphoma | Abstract C35

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-For-Service Beneficiaries Newly Diagnosed With Peripheral T-Cell Lymphoma